Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
AssigneeThe Government of the United States as represented by the Secretary of the Department of Health and Human Services
InventorsJames A. Braatz, Kenneth R. McIntire, Gerald L. Princler
Life of this patent
Estimating the term…
Abstract
The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.
Claims17
A substantially purified human lung tumor-associated antigen (hLTAA) associated with lung tumors comprising small cell carcinomas, large cell undifferentiated carcinomas, squamous cell carcinomas and adenocarcinomas, characterized by
- a diffusion coefficient (D.sub.20,w) of 4.2-4.3.times.10.sup.-7 cm.sup.2 sec.sup.-1, a sedimentation coefficient (S.sub.20,w) of 4.5-4.6 S;
- and a Stokes radius of 51 .ANG.;
- immunological reactivity with a xenoantiserum containing heterologous species antibodies raised in a heterologous species animal as an immune response to a crude extract of at least one of said lung tumors;
- and
- no antigenic cross-reactivity with .alpha..sub.1 -antichymotrypsin.
Dependencies are inferred from the claim text.